These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 37654497)

  • 1. Beyond αβ T cells: NK, iNKT, and γδT cell biology in leukemic patients and potential for off-the-shelf adoptive cell therapies for AML.
    Kent A; Crump LS; Davila E
    Front Immunol; 2023; 14():1202950. PubMed ID: 37654497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of Frequencies, Compositions, and/or Antileukemic Activity of (DC-stimulated) Invariant NKT, NK and CIK Cells on the Outcome of Patients With AML, ALL and CLL.
    Boeck CL; Amberger DC; Doraneh-Gard F; Sutanto W; Guenther T; Schmohl J; Schuster F; Salih H; Babor F; Borkhardt A; Schmetzer H
    J Immunother; 2017; 40(6):224-248. PubMed ID: 28557814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies.
    Soldierer M; Bister A; Haist C; Thivakaran A; Cengiz SC; Sendker S; Bartels N; Thomitzek A; Smorra D; Hejazi M; Uhrberg M; Scheckenbach K; Monzel C; Wiek C; Reinhardt D; Niktoreh N; Hanenberg H
    Front Immunol; 2022; 13():847008. PubMed ID: 35464442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive Cellular Therapy in Acute Myeloid Leukemia: Current Scope and Challenges.
    Arora S; Asawa P; Ramakrishnan A; Bachier C; Majhail NS
    Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):159-167. PubMed ID: 36537907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia.
    Caruso S; De Angelis B; Del Bufalo F; Ciccone R; Donsante S; Volpe G; Manni S; Guercio M; Pezzella M; Iaffaldano L; Silvestris DA; Sinibaldi M; Di Cecca S; Pitisci A; Velardi E; Merli P; Algeri M; Lodi M; Paganelli V; Serafini M; Riminucci M; Locatelli F; Quintarelli C
    J Hematol Oncol; 2022 Nov; 15(1):163. PubMed ID: 36335396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia.
    Gurney M; O'Dwyer M
    Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33805422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Target tumor microenvironment by innate T cells.
    Li YR; Wilson M; Yang L
    Front Immunol; 2022; 13():999549. PubMed ID: 36275727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric Antigen Receptor T-cell Therapy for Acute Myeloid Leukemia.
    Bi X; Hsu J; Gergis M; Yang Y; Yi D; Gergis U
    Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):131-136. PubMed ID: 36537909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ligand-based targeting of c-kit using engineered γδ T cells as a strategy for treating acute myeloid leukemia.
    Branella GM; Lee JY; Okalova J; Parwani KK; Alexander JS; Arthuzo RF; Fedanov A; Yu B; McCarty D; Brown HC; Chandrakasan S; Petrich BG; Doering CB; Spencer HT
    Front Immunol; 2023; 14():1294555. PubMed ID: 38022523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Immune Cell-Based Therapies to Eradicate High-Risk Acute Myeloid Leukemia.
    Limongello R; Marra A; Mancusi A; Bonato S; Hoxha E; Ruggeri L; Hui S; Velardi A; Pierini A
    Front Immunol; 2021; 12():695051. PubMed ID: 34413848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoptive cell therapy for acute myeloid leukemia.
    Ma H; Padmanabhan Iyer S; Parmar S; Gong Y
    Leuk Lymphoma; 2019 Jun; 60(6):1370-1380. PubMed ID: 30628504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond CAR T cells: exploring alternative cell sources for CAR-like cellular therapies.
    Tsiverioti CA; Gottschlich A; Trefny M; Theurich S; Anders HJ; Kroiss M; Kobold S
    Biol Chem; 2024 Jul; 405(7-8):485-515. PubMed ID: 38766710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Evaluation of CRISPR-Edited CAR-NK-92 Cells for Off-the-Shelf Treatment of AML and B-ALL.
    Ureña-Bailén G; Dobrowolski JM; Hou Y; Dirlam A; Roig-Merino A; Schleicher S; Atar D; Seitz C; Feucht J; Antony JS; Mohammadian Gol T; Handgretinger R; Mezger M
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
    Driouk L; Gicobi JK; Kamihara Y; Rutherford K; Dranoff G; Ritz J; Baumeister SHC
    Front Immunol; 2020; 11():580328. PubMed ID: 33384686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
    Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
    Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immune cell therapy for acute myeloid leukemia].
    Nakazawa Y
    Rinsho Ketsueki; 2023; 64(9):942-948. PubMed ID: 37793869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
    Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia.
    Trad R; Warda W; Alcazer V; Neto da Rocha M; Berceanu A; Nicod C; Haderbache R; Roussel X; Desbrosses Y; Daguindau E; Renosi F; Roumier C; Bouquet L; Biichle S; Guiot M; Seffar E; Caillot D; Depil S; Robinet E; Salma Y; Deconinck E; Deschamps M; Ferrand C
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35803613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
    Story JY; Zoine JT; Burnham RE; Hamilton JAG; Spencer HT; Doering CB; Raikar SS
    Cytotherapy; 2021 Jan; 23(1):12-24. PubMed ID: 33168453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric Antigen Receptor (CAR)-Modified Immune Effector Cell Therapy for Acute Myeloid Leukemia (AML).
    Acharya UH; Walter RB
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33287224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.